Paragon 28 (NYSE:FNA – Get Free Report) and STRATA Skin Sciences (NASDAQ:SSKN – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, earnings and dividends.
Insider & Institutional Ownership
63.6% of Paragon 28 shares are held by institutional investors. Comparatively, 32.4% of STRATA Skin Sciences shares are held by institutional investors. 15.3% of Paragon 28 shares are held by company insiders. Comparatively, 39.0% of STRATA Skin Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Paragon 28 and STRATA Skin Sciences”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Paragon 28 | $245.00 million | 3.45 | -$57.53 million | ($0.74) | -13.64 |
| STRATA Skin Sciences | $32.68 million | 0.37 | -$10.83 million | ($2.66) | -1.08 |
Risk & Volatility
Paragon 28 has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Comparatively, STRATA Skin Sciences has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500.
Profitability
This table compares Paragon 28 and STRATA Skin Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Paragon 28 | -25.31% | -37.90% | -18.22% |
| STRATA Skin Sciences | -28.72% | -69.33% | -17.55% |
Analyst Recommendations
This is a breakdown of recent recommendations for Paragon 28 and STRATA Skin Sciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Paragon 28 | 0 | 0 | 4 | 1 | 3.20 |
| STRATA Skin Sciences | 0 | 0 | 0 | 0 | 0.00 |
Paragon 28 presently has a consensus target price of $15.60, suggesting a potential upside of 54.61%. Given Paragon 28’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Paragon 28 is more favorable than STRATA Skin Sciences.
Summary
Paragon 28 beats STRATA Skin Sciences on 11 of the 15 factors compared between the two stocks.
About Paragon 28
Paragon 28, Inc. develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; APEX 3D total ankle replacement systems; and total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides forefoot or hallux valgus correction systems, including phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.
About STRATA Skin Sciences
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. The company products include XTRAC and Pharos excimer lasers, and VTRAC lamp systems for the treatment systems that are used for the treatment of psoriasis, vitiligo, and other skin conditions. It also offers TheraClear Acne Therapy System for the treatment of mild to moderate inflammatory, comedonal, and pustular acne. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.
Receive News & Ratings for Paragon 28 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paragon 28 and related companies with MarketBeat.com's FREE daily email newsletter.
